Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × elotuzumab × Clear all

Phase

Phase 2 7 Phase 3 1

Status

Recruiting 4 Completed 4 Active not recruiting 3 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

Cisplatin 21 Carboplatin 15 Radiotherapy 12 Paclitaxel 11 Gemcitabine 10 Rituximab 9 Fluorouracil 9 Drug Therapy 6 Dexamethasone 5 Cyclophosphamide 5 Capecitabine 5 Bevacizumab 5 Vinorelbine 4 Pemetrexed 4 Nivolumab 4 Methotrexate 4 Docetaxel 4 Bendamustine Hydrochloride 4 spartalizumab 3 pertuzumab 3 pembrolizumab 3 fludarabine 3 Vincristine 3 Trastuzumab 3 Surgical Procedures, Operative 3 Standard of Care 3 Prednisone 3 Oxaliplatin 3 Lenalidomide 3 Etoposide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06232707 2024-05-31

ALUMMINATE

Celgene

Phase 3 Withdrawn

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡